Cardiac ArrestOPTIVONCT07479836
Optimizing Ventilation to Improve Survival From Out-of-hospital Cardiac Arrest: the OPTIVO Randomized Controlled Trial
A study testing Low Volume Ventilation and High Volume Ventilation in people with Cardiac Arrest, run by Sunnybrook Health Sciences Centre at 1 site in Canada.
Trial summary
When the heart stops pumping during cardiac arrest, cardiopulmonary resuscitation (CPR) is used to continue pushing blood and providing oxygen to vital organs. CPR involves a combination of chest compressions (to push the blood) and ventilations (to provide oxygen and gas exchange). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cardiac Arrest
- What is being tested?
- Low Volume Ventilation and High Volume Ventilation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,656 participants
- Where
- 1 siteCanada
- Study dates
- Mar 2026to Mar 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult (>=18 years of age)
- presumed cardiac etiology
- treated by paramedics
- Ventilation monitor utilized
Who cannot join
- Do Not Resuscitate (DNR) order
- No use of ventilation monitor
- Traumatic cardiac arrest
- Pregnant patients
- Prisoners
- Respiratory cause of cardiac arrest (e.g. drowning, hanging, suffocation, opioid-related)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N3M5
Ian Drennan, PhD, 416-667-2200 ext. 0, ian.drennan@sunnybrook.ca
About this study
Official title: OPTImizing Ventilation to Improve Survival From Out-of-Hospital Cardiac Arrest: The OPTIVO Randomized Controlled Trial
When the heart stops pumping during cardiac arrest, cardiopulmonary resuscitation (CPR) is used to continue pushing blood and providing oxygen to vital organs. CPR involves a combination of chest compressions (to push the blood) and ventilations (to provide oxygen and gas exchange). There is a lot of research that has helped to optimize the provision of chest compressions, however there is considerably less research available to guide ventilations. The current guideline recommendations are based on limited data, and no data that is specific to cardiac arrest patients. There is a recognized need for research to better guide ventilation during CPR. This research will help to better define appropriate ventilation targets for cardiac arrest patients.
Read the detailed description
Rationale Chest compressions and ventilations are the two primary components of cardiopulmonary resuscitation (CPR); one of the few treatments to get a Class 1 recommendation from the American Heart Association (AHA) guidelines for the treatment of patients in cardiac arrest. While there is a significant body of literature examining chest compression quality the evidence regarding optimal ventilation quality is limited.
Current guidelines recommend providing ventilations of 500-600ml, or enough for chest rise, to adult patients in cardiac arrest in either a 30:2 ventilation to chest compression ratio without an advanced airway or one breath every six seconds (10 per minute) with an advanced airway. Little has changed in these recommendations over the last 10 years. It is recognized, however, that the evidence informing these recommendations is based on limited, low-quality evidence from non-cardiac arrest populations. Both the International Liaison Committee on Resuscitation (ILCOR) and the AHA have identified that there remains a significant knowledge gap with respect to optimal ventilation strategies during out-of-hospital cardiac arrest (OHCA) resuscitation.
Hyperventilation and Hypoventilation Proper ventilation during cardiac arrest is important to provide oxygenation to vital organs, such as the brain, and remove harmful metabolism by-products (e.g. carbon dioxide). Improper ventilation, both hypoventilation (too little) and hyperventilation (too much) can be detrimental to patient survival and neurological outcomes. What constitutes optimal ventilation, however, is unknown.
Hypoventilation can lead to increased ischemic injury from reduced oxygen delivery to the brain during cardiac arrest. It can also cause a build-up of CO2 resulting in a respiratory acidosis which can have detrimental consequences to the heart and cardiovascular function. The amount of ventilation that is required during cardiac arrest though is not known. Research examining passive oxygenation (no active ventilation) demonstrates mixed results with respect to cardiac arrest outcomes. While outcomes have been mixed, in general passive oxygenation may not provide sufficient tidal volumes (often under 20mL) generated with chest compressions for adequate gas exchange.
Hyperventilation can lead to air-trapping and an increase in intrathoracic pressure, leading to increased right atrial pressure, decreased coronary perfusion pressure, and decreased venous return and cardiac output.9 During positive pressure ventilation, the increase in intrathoracic pressure during inspiration leads to a decrease in right ventricular preload, ultimately decreasing cardiac output. Decreased cardiac output and coronary perfusion lead to reduced rates of return of spontaneous circulation, which ultimately leads to reduced survival. Aggressive ventilations can also cause gastric insufflation and gastric regurgitation leading to pneumonia and other associated airway complications. Previous research has shown that ventilation with lower volumes (365mL) is associated with lower airway pressures, and reduced incidence of gastric insufflation without changes in oxygen saturation. Similarly, ventilations with 6mL/kg result in same CO2 clearance as larger tidal volumes. Furthermore, research examining end-tidal CO2 tracings has hypothesized that hyperinflation is a common phenomenon during cardiac arrest.
Performance of Ventilation During Cardiac Arrest
Proper ventilations during cardiac resuscitation are challenging to perform. Chang et al. (2019) found that lung inflation occurred infrequently during pauses in chest compressions, however, that an increased number of ventilations were associated with increased rates of ROSC and survival to hospital discharge. Vissers et al. (2019) found no correlation between ventilation rate and ROSC, however found that hyperventilation was common, occurring in 85% of resuscitations. Variability in patient characteristics and logistical challenges, such as limited physical space, make it difficult to perform consistent high-quality ventilations.
While AHA guideline indicate 500 to 600mL of volume per ventilation, recognition of chest rise often occurs at volumes that are significantly lower. This creates a conflict within the AHA recommendation on the appropriate volume of ventilation. Chest rise has been shown to occur at volumes 362 to 402mL with an average of 384mL.
Previous Literature
There is a paucity of high-quality evidence to support current ventilation guideline recommendations, and the available evidence lacks patient-oriented outcomes such as survival to hospital discharge, or neurological outcome. Evidence for ventilations during cardiac arrest is mostly borrowed from animal research or anesthesiology literature indicating that ventilations of 6 to 8 ml/kg of ideal body weight is sufficient in patients in respiratory arrest and is enough volume to create visible chest rise. This volume has not been demonstrated to be sufficient, nor ideal in the cardiac arrest population. It is known that cardiac output is approximately 30% of normal during chest compressions and therefore ventilation requirements may also be different.
Previous research has found that passive insufflation is as effective as positive pressure ventilation, at least during the first few minutes of witnessed cardiac arrest resuscitation which begs the question of how much ventilation is required. Other research examining ventilation quality has found decreased survival associated with hyperventilation. A small observational study by Sutton et al. (2019) found a decrease in survival and neurological outcome in paediatric patients with both low and high ventilation rates. They also identified that the 'sweet spot' for ventilation rate, that was associated with the highest survival and neurological outcome, was higher than recommended by the AHA guidelines.
One significant barrier to optimizing ventilations during OHCA has been the inability to accurately measure the quality of ventilations being performed by paramedics in the field. Until recently there has been no method available in the prehospital setting to provide accurate, real-time measurement and feedback of ventilation rate and/or volume. Utilization of feedback devices has been shown to improve the quality of chest compressions performed in the field. Similarly the use of tidal volume feedback devices has been shown to improve the proportion of ventilations within target range during simulated cardiac arrest resuscitation. A simulation study using the ZOLL Accuvent® ventilation monitor found that ventilations significantly improved with the use of real-time feedback during simulated cardiac arrests. The authors found that the use of real-time feedback resulted in a increase in target compliance for ventilation rate from 41% to 71%, ventilation volume from 31% to 79% and for rate and volume together from 10% to 63%. Similarly, Lyngby et al. (2021) performed a randomized controlled trial with 64 paramedics using simulated cardiac arrest scenarios. They found that use of real-time feedback was able to significantly improve guideline compliance in terms of ventilation rate and volume as combined or individual parameters. Charlton et al. (2021) found similar results in 106 paramedics when performing 2-minute simulated scenarios.
Our previous publication is the only published literature examining ventilation during cardiac arrest with ventilation feedback devices. We identified that without feedback, ventilations rarely meet guideline recommendations, however compliance significantly improved with ventilation feedback. The average ventilation volume was much lower than guideline targets (395mL).
Significance of the project
This study will constitute the most rigorous evaluation of the impact of ventilations during cardiac arrest on patient outcomes. This is an area of research that is of huge importance but is significantly under studied as until recently it was not possible to reliably measure ventilation quality in the field. There are significant knowledge gaps in our understanding of the importance of ventilations during resuscitation and what are the key indicators of ventilation quality. Multiple simulation studies have indicated that use of real-time feedback significantly improves the quality of ventilations performed by paramedics, however none of these studies were on real patients, performed in the field, or had any patient-oriented outcomes associated with them.
This study will build upon previous simulation studies to examine real-time feedback in the field during actual cardiac arrests and examine the association of ventilations with patient outcomes. The results of this study will have guideline informing implications, leading to improvements in clinical practice. These improvements in care could lead to increased survival from out-of-hospital cardiac arrest. Further, this research will lead to other important questions regarding the relationship between ventilations, cardiac arrest care, prognostication and patient outcomes.
- Conditions
- Cardiac Arrest
- Being tested
- Low Volume Ventilation, High Volume Ventilation
- Keywords
- Resuscitation, Ventilation, Cardiopulmonary Resuscitation, Out-of-Hospital Cardiac Arrest
- Medical subject headings
- Heart Arrest, Respiratory Aspiration, Out-of-Hospital Cardiac Arrest
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low Volume VentilationOther
Patients in cardiac arrest will be ventilated with a volume of 350ml (+/- 50 ml)
High Volume VentilationOther
600ml (+/-50ml)
| Study group | Role | What they receive |
|---|---|---|
| Low Volume (350ml (+/50ml) | Experimental | Not described Receives: Other: Low Volume Ventilation |
| 600ml (+/-50ml) | Active comparator | Not described Receives: Other: High Volume Ventilation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Return of Spontaneous Circulation
At any time in the prehospital setting as documented by paramedics
Measured: Prior to arrival at the hospital. This will occur within 1 hr after enrolment in most patients.
Secondary outcomes (2)
Survival to Hospital Discharge
Survival at hospital discharge
Measured: Discharge from hospital is likely to occur within 30 days of the cardiac arrest event for most patients.
Survival to Hospital Admission
Survival to hospital admission obtained through administrative datasets
Measured: Hospital Admission - estimated to occur within 6 hrs of arrival at hospital for most patients.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Mar 2026
- Study startMar 2026 (estimated)
- Primary completionJan 2028 (estimated)
- Study completionMar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiac ArrestStudies of the same condition, open and under way.
- More trials run by Sunnybrook Health Sciences CentreThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Cluster Crossover Clinical Trial
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 1,656 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sunnybrook Health Sciences Centre
- Sponsor type
- University, hospital or other
- Collaborators
- Zoll Medical Corporation
- Responsible party
- Principal investigator, Ian Drennan, Sunnybrook Health Sciences Centre
- Investigators
- Ian Drennan, PhD, Principal investigator, Sunnybrook Health Sciences CentreSheldon Cheskes, MD, Principal investigator, Sunnybrook Health Sciences Centre
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07479836
- Sponsor's protocol ID
- 5783
- Acronym
- OPTIVO
- Status last verified
- Mar 2026
- First submitted
- 2 Mar 2026
- Last updated
- 18 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 18 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- OPTImizing Ventilation to Improve Survival From Out-of-Hospital Cardiac Arrest: The OPTIVO Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07479836
- Acronym / sponsor ID
- OPTIVO / 5783
- Conditions
- Cardiac Arrest
- Keywords
- Resuscitation, Ventilation, Cardiopulmonary Resuscitation, Out-of-Hospital Cardiac Arrest
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 1,656 participants (estimated)
- Lead sponsor
- Sunnybrook Health Sciences CentreUniversity, hospital or other
- Collaborators
- Zoll Medical Corporation
- Study start
- Mar 2026 (estimated)
- Primary completion
- Jan 2028 (estimated)
- Study completion
- Mar 2028 (estimated)
- First posted
- 18 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
When the heart stops pumping during cardiac arrest, cardiopulmonary resuscitation (CPR) is used to continue pushing blood and providing oxygen to vital organs. CPR involves a combination of chest compressions (to push the blood) and ventilations (to provide oxygen and gas exchange). There is a lot of research that has helped to optimize the provision of chest compressions, however there is considerably less research available to guide ventilations. The current guideline recommendations are based on limited data, and no data that is specific to cardiac arrest patients. There is a recognized need for research to better guide ventilation during CPR. This research will help to better define appropriate ventilation targets for cardiac arrest patients.
Detailed description
Rationale Chest compressions and ventilations are the two primary components of cardiopulmonary resuscitation (CPR); one of the few treatments to get a Class 1 recommendation from the American Heart Association (AHA) guidelines for the treatment of patients in cardiac arrest. While there is a significant body of literature examining chest compression quality the evidence regarding optimal ventilation quality is limited.
Current guidelines recommend providing ventilations of 500-600ml, or enough for chest rise, to adult patients in cardiac arrest in either a 30:2 ventilation to chest compression ratio without an advanced airway or one breath every six seconds (10 per minute) with an advanced airway. Little has changed in these recommendations over the last 10 years. It is recognized, however, that the evidence informing these recommendations is based on limited, low-quality evidence from non-cardiac arrest populations. Both the International Liaison Committee on Resuscitation (ILCOR) and the AHA have identified that there remains a significant knowledge gap with respect to optimal ventilation strategies during out-of-hospital cardiac arrest (OHCA) resuscitation.
Hyperventilation and Hypoventilation Proper ventilation during cardiac arrest is important to provide oxygenation to vital organs, such as the brain, and remove harmful metabolism by-products (e.g. carbon dioxide). Improper ventilation, both hypoventilation (too little) and hyperventilation (too much) can be detrimental to patient survival and neurological outcomes. What constitutes optimal ventilation, however, is unknown.
Hypoventilation can lead to increased ischemic injury from reduced oxygen delivery to the brain during cardiac arrest. It can also cause a build-up of CO2 resulting in a respiratory acidosis which can have detrimental consequences to the heart and cardiovascular function. The amount of ventilation that is required during cardiac arrest though is not known. Research examining passive oxygenation (no active ventilation) demonstrates mixed results with respect to cardiac arrest outcomes. While outcomes have been mixed, in general passive oxygenation may not provide sufficient tidal volumes (often under 20mL) generated with chest compressions for adequate gas exchange.
Hyperventilation can lead to air-trapping and an increase in intrathoracic pressure, leading to increased right atrial pressure, decreased coronary perfusion pressure, and decreased venous return and cardiac output.9 During positive pressure ventilation, the increase in intrathoracic pressure during inspiration leads to a decrease in right ventricular preload, ultimately decreasing cardiac output. Decreased cardiac output and coronary perfusion lead to reduced rates of return of spontaneous circulation, which ultimately leads to reduced survival. Aggressive ventilations can also cause gastric insufflation and gastric regurgitation leading to pneumonia and other associated airway complications. Previous research has shown that ventilation with lower volumes (365mL) is associated with lower airway pressures, and reduced incidence of gastric insufflation without changes in oxygen saturation. Similarly, ventilations with 6mL/kg result in same CO2 clearance as larger tidal volumes. Furthermore, research examining end-tidal CO2 tracings has hypothesized that hyperinflation is a common phenomenon during cardiac arrest.
Performance of Ventilation During Cardiac Arrest
Proper ventilations during cardiac resuscitation are challenging to perform. Chang et al. (2019) found that lung inflation occurred infrequently during pauses in chest compressions, however, that an increased number of ventilations were associated with increased rates of ROSC and survival to hospital discharge. Vissers et al. (2019) found no correlation between ventilation rate and ROSC, however found that hyperventilation was common, occurring in 85% of resuscitations. Variability in patient characteristics and logistical challenges, such as limited physical space, make it difficult to perform consistent high-quality ventilations.
While AHA guideline indicate 500 to 600mL of volume per ventilation, recognition of chest rise often occurs at volumes that are significantly lower. This creates a conflict within the AHA recommendation on the appropriate volume of ventilation. Chest rise has been shown to occur at volumes 362 to 402mL with an average of 384mL.
Previous Literature
There is a paucity of high-quality evidence to support current ventilation guideline recommendations, and the available evidence lacks patient-oriented outcomes such as survival to hospital discharge, or neurological outcome. Evidence for ventilations during cardiac arrest is mostly borrowed from animal research or anesthesiology literature indicating that ventilations of 6 to 8 ml/kg of ideal body weight is sufficient in patients in respiratory arrest and is enough volume to create visible chest rise. This volume has not been demonstrated to be sufficient, nor ideal in the cardiac arrest population. It is known that cardiac output is approximately 30% of normal during chest compressions and therefore ventilation requirements may also be different.
Previous research has found that passive insufflation is as effective as positive pressure ventilation, at least during the first few minutes of witnessed cardiac arrest resuscitation which begs the question of how much ventilation is required. Other research examining ventilation quality has found decreased survival associated with hyperventilation. A small observational study by Sutton et al. (2019) found a decrease in survival and neurological outcome in paediatric patients with both low and high ventilation rates. They also identified that the 'sweet spot' for ventilation rate, that was associated with the highest survival and neurological outcome, was higher than recommended by the AHA guidelines.
One significant barrier to optimizing ventilations during OHCA has been the inability to accurately measure the quality of ventilations being performed by paramedics in the field. Until recently there has been no method available in the prehospital setting to provide accurate, real-time measurement and feedback of ventilation rate and/or volume. Utilization of feedback devices has been shown to improve the quality of chest compressions performed in the field. Similarly the use of tidal volume feedback devices has been shown to improve the proportion of ventilations within target range during simulated cardiac arrest resuscitation. A simulation study using the ZOLL Accuvent® ventilation monitor found that ventilations significantly improved with the use of real-time feedback during simulated cardiac arrests. The authors found that the use of real-time feedback resulted in a increase in target compliance for ventilation rate from 41% to 71%, ventilation volume from 31% to 79% and for rate and volume together from 10% to 63%. Similarly, Lyngby et al. (2021) performed a randomized controlled trial with 64 paramedics using simulated cardiac arrest scenarios. They found that use of real-time feedback was able to significantly improve guideline compliance in terms of ventilation rate and volume as combined or individual parameters. Charlton et al. (2021) found similar results in 106 paramedics when performing 2-minute simulated scenarios.
Our previous publication is the only published literature examining ventilation during cardiac arrest with ventilation feedback devices. We identified that without feedback, ventilations rarely meet guideline recommendations, however compliance significantly improved with ventilation feedback. The average ventilation volume was much lower than guideline targets (395mL).
Significance of the project
This study will constitute the most rigorous evaluation of the impact of ventilations during cardiac arrest on patient outcomes. This is an area of research that is of huge importance but is significantly under studied as until recently it was not possible to reliably measure ventilation quality in the field. There are significant knowledge gaps in our understanding of the importance of ventilations during resuscitation and what are the key indicators of ventilation quality. Multiple simulation studies have indicated that use of real-time feedback significantly improves the quality of ventilations performed by paramedics, however none of these studies were on real patients, performed in the field, or had any patient-oriented outcomes associated with them.
This study will build upon previous simulation studies to examine real-time feedback in the field during actual cardiac arrests and examine the association of ventilations with patient outcomes. The results of this study will have guideline informing implications, leading to improvements in clinical practice. These improvements in care could lead to increased survival from out-of-hospital cardiac arrest. Further, this research will lead to other important questions regarding the relationship between ventilations, cardiac arrest care, prognostication and patient outcomes.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- Cluster Crossover Clinical Trial
| Arm | Type | Receives |
|---|---|---|
| Low Volume (350ml (+/50ml) | Experimental | Other: Low Volume Ventilation |
| 600ml (+/-50ml) | Active comparator | Other: High Volume Ventilation |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adult (>=18 years of age)
- presumed cardiac etiology
- treated by paramedics
- Ventilation monitor utilized
Key exclusion criteria (6 listed)
- Do Not Resuscitate (DNR) order
- No use of ventilation monitor
- Traumatic cardiac arrest
- Pregnant patients
- Prisoners
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Low Volume VentilationPatients in cardiac arrest will be ventilated with a volume of 350ml (+/- 50 ml) | Other | Low Volume (350ml (+/50ml) |
| High Volume Ventilation600ml (+/-50ml) | Other | 600ml (+/-50ml) |
Primary outcome
Return of Spontaneous Circulation
Time frame: Prior to arrival at the hospital. This will occur within 1 hr after enrolment in most patients.
At any time in the prehospital setting as documented by paramedics
2 secondary outcomes
Survival to Hospital Discharge
Time frame: Discharge from hospital is likely to occur within 30 days of the cardiac arrest event for most patients.
Survival to Hospital Admission
Time frame: Hospital Admission - estimated to occur within 6 hrs of arrival at hospital for most patients.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Mar 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Cardiac Arrest
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruitingObservational study
CAROTID DOPPLER AND CEREBRAL OXIMERY IN POST CARDIAC ARREST ICU PATIENTS
Cardiac Arrest (CA), Carotid Doppler
Active, not recruitingPhase 3
The Danish Out-of-Hospital Cardiac Arrest Study
Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest Syndrome
RecruitingObservational study
Evaluation of Acid-base Disorders and Ventilation Settings in Cardiogenic Shock and Post-cardiac Arrest Patients: Comparison With VentilO Algorithm
Cardiac Arrest (CA), Cardiogenic Shock
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ian Drennan, PhD principal investigator
Sunnybrook Health Sciences Centre
Sheldon Cheskes, MD principal investigator
Sunnybrook Health Sciences Centre
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Low Volume Ventilation and High Volume Ventilation in people with Cardiac Arrest, run by Sunnybrook Health Sciences Centre at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 18 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ian Drennan, PhD (416-667-2200 ext. 0, ian.drennan@sunnybrook.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Return of Spontaneous Circulation (time frame: Prior to arrival at the hospital. This will occur within 1 hr after enrolment in most patients.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Mar 2026.